Nasdaq Corporate Solutions and Euroland IR Partner to Provide Enhanced Features for Investor Relations Websites
STOCKHOLM, Sweden, 2017-01-30 10:05 CET (GLOBE NEWSWIRE) --
Nasdaq Corporate Solutions announces its partnership with Euroland IR to offer investor relations (IR) professionals worldwide with enhanced features for their IR websites. The partnership was formalized in December 2016 and brings comprehensive stock quotes, interactive charting and other IR website modules to thousands of Nasdaq Corporate Solutions clients across EMEA, Asia and the Americas. This upgrade for clients is already underway and follows the release of Nasdaq’s next generation IR website platform powered by Drupal 8 open source technology.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8e024557-1d6b-4567-8dc5-86ff79c4a506
“Euroland is a demonstrated leader in mobile-friendly stock quotes and interactive charting functions and we are thrilled to bring the industry’s best features to our IR website clients,” said Stacie Swanstrom, Executive Vice President and Head of Nasdaq Corporate Solutions. “We are confident in the partnership and in our ability to ensure a seamless and improved IR website experience for our clients.”
“Euroland IR is proud to partner with Nasdaq Corporate Solutions, who work constantly to enhance and improve their clients' IR communication on a worldwide basis,” said Natalie Kahn, CEO of Euroland IR. “Together we will ensure that Nasdaq Corporate Solutions’ clients experience the best possible service.”
Nasdaq Corporate Solutions, a business line of Nasdaq, Inc. (Nasdaq:NDAQ), provides an integrated suite of market intelligence, communications, workflow and collaboration solutions for corporate executives and boards to nearly 18,000 corporate clients. The product suite comprises products that support investor relations, corporate communications and corporate governance functions. Nasdaq Corporate Solutions builds, hosts and maintains IR websites for more than 3,000 companies worldwide, including approximately 78 percent of the Nasdaq-100 Index and approximately 63 percent of the Fortune 500.
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables clients to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 85 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,800 listed companies with a market value of $10.1 trillion and nearly 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
Nasdaq Media Contact:
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
Corporate R&D spending hits record highs for the Top 1000, despite concerns of economic protectionism24.10.2017 08:00 | Pressemelding
Annual worldwide R&D spending breaks through $700bn for the top 1000 corporate R&D spenders for first time 25% of executives surveyed reported having already experienced some pressure to change how or where they conduct innovation Amazon is the world's largest corporate spender on R&D at over $16bn Alphabet surpasses Apple, according to a global survey of R&D executives, as the Most Innovative Company and for the first time a Chinese company, Alibaba joins the Top 10 Most Innovative Companies list NEW YORK, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Annual worldwide corporate R&D spending broke through $700bn in annual investment, according to an annual analysis of R&D spending across 1000 global public companies by P
TEAM Industries Announces New Innovative Transmission Incorporating Fallbrook's NuVinci® CVP Technology24.10.2017 02:25 | Pressemelding
Design is ready for vehicle implementation in powered recreational and utility vehicles CEDAR PARK, TEXAS and BAGLEY, MINNESOTA, Oct. 23, 2017 (GLOBE NEWSWIRE) -- TEAM Industries (TEAM) and Fallbrook Technologies Inc. (Fallbrook) announced today that TEAM has a production-ready innovative new transmission design for all-terrain vehicles (ATV) and utility task vehicles (UTV) available to OEMs for vehicle implementation. The transmission incorporates Fallbrook's NuVinci® continuously variable planetary (CVP) technology. NuVinci is a platform technology for a new class of continuously variable transmissions (CVT). It utilizes spheres instead of gears or belts, and can be deployed in a wide variety of applications to improve performance and/or system efficiency. TEAM has an exclusive licensing agreement with Fallbrook for the use of NuVinci CVP technology in North America and Europe in electric and gasoline light vehicle applications. TEAM is also workin
Telix Pharmaceuticals and ANMI Partner for Prostate Cancer Imaging24.10.2017 01:00 | Pressemelding
MELBOURNE, Australia and LIÈGE, Belgium, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, Company), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR), is pleased to announce that it has entered into a development and commercialization partnership with Advanced Nuclear Medicine Ingredients SA (ANMI). Under the terms of the agreement, Telix and ANMI will partner to commercialise ANMI's 68Ga-HBED-CC-PSMA (68Ga-PSMA-11) kit (Kit), a proven technology used to accurately image and stage metastatic prostate cancer, in the US market. Telix will also offer the Kit on a worldwide basis as a companion diagnostic imaging agent to the Company's prostate cancer therapeutic (TLX-591)1. The agreement includes filing a Drug Master File (DMF) for the Kit, and completion of the necessary clinical trials to obtain marketing authorisatio
Telix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)23.10.2017 23:00 | Pressemelding
MELBOURNE, Australia, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, the Company), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), is pleased to announce the opening of its Initial Public Offering (IPO or Offer) to raise A$50 million. The IPO is an offer by Telix for the issue of 77.0 million shares at $0.65 per share and is fully underwritten by the Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited. The IPO has been strongly supported by the Company's existing shareholders, which include both industry partners and domestic institutional investors, such as Acorn Capital, CVC, Monash Investors, Viburnum Funds, Allan Moss and Alium Capital Management. With this Offer, Telix will further strengthen its Australian and international institutional shareholder base, including the addition of Fidel
Brookfield Asset Management Notice of 2017 Q3 Results Conference Call and Webcast23.10.2017 17:03 | Pressemelding
Date: Thursday, November 9, 2017 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, News, Oct. 23, 2017 (GLOBE NEWSWIRE) -- You are invited to participate in Brookfield Asset Management's 2017 Third Quarter Conference Call & Webcast on Thursday, November 9, 2017 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on November 9th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com "News - Press Releases." The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-800-319-4610 toll free in North America, or for overseas calls please dial 1-604-638-5340 at approximately 10:50 a.m. The Conference Call will also be Webcast live at http://servic
Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines23.10.2017 13:00 | Pressemelding
LOWELL, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the receipt of a $7.3 million contract from the Biomedical Advanced Research and Development Authority (BARDA) for the implementation of a rapid sterility test for vaccines. This awarded grant is part of BARDA's Advance Development of Medical Countermeasures for Pandemic Influenza, which focuses on improving the government's responsiveness to future pandemic threats. When combined with Rapid Micro Biosystems' automated Growth Direct(TM) detection system, the rapid sterility test will result in faster release of vaccines and other sterile products. Timely delivery of these products carries multiple public benefits, principally in facilitating rapid responses to pandemic or emerging infections, agents of bioterrorism, and availability of life saving medicines. "Our continuing relationship with BARDA demonstrate
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom